Immunization News and Research

RSS
Maternal and perinatal outcomes of women infected with SARS-CoV-2 during the Omicron wave in Italy

Maternal and perinatal outcomes of women infected with SARS-CoV-2 during the Omicron wave in Italy

New study evaluates the safety profile of the BNT162b2 vaccine in New Zealand

New study evaluates the safety profile of the BNT162b2 vaccine in New Zealand

Researchers identify potent pan-sarbecovirus antibodies from non-human primates vaccinated with an AS03 adjuvanted subunit SARS-CoV-2 vaccine

Researchers identify potent pan-sarbecovirus antibodies from non-human primates vaccinated with an AS03 adjuvanted subunit SARS-CoV-2 vaccine

What was the prevalence of adverse events following first and second dose COVID-19 vaccinations in England?

What was the prevalence of adverse events following first and second dose COVID-19 vaccinations in England?

Bivalent BA.4-5 or BA.1 mRNA-booster given as a fourth dose associated with increased protection against COVID-19 hospitalization and death

Bivalent BA.4-5 or BA.1 mRNA-booster given as a fourth dose associated with increased protection against COVID-19 hospitalization and death

Phase I trial results from AdaptVac's COVID capsid virus-like particle vaccine

Phase I trial results from AdaptVac's COVID capsid virus-like particle vaccine

Researchers find that study results converge on a consistent relationship between antibody levels and protection from COVID-19

Researchers find that study results converge on a consistent relationship between antibody levels and protection from COVID-19

Future COVID-19 control will require vaccines that induce better mucosal immunity

Future COVID-19 control will require vaccines that induce better mucosal immunity

Study finds non-Omicron breakthrough infections elicit robust cross-neutralizing activity against Omicron variants across the antigenic barrier

Study finds non-Omicron breakthrough infections elicit robust cross-neutralizing activity against Omicron variants across the antigenic barrier

What is the effectiveness of a multivalent exosome-based COVID-19 vaccine?

What is the effectiveness of a multivalent exosome-based COVID-19 vaccine?

What is the efficacy of the COVID-19 second booster versus the first booster with prior COVID-19 infections?

What is the efficacy of the COVID-19 second booster versus the first booster with prior COVID-19 infections?

What are the present challenges and future considerations in developing vaccines against mucosal respiratory viruses?

What are the present challenges and future considerations in developing vaccines against mucosal respiratory viruses?

The impact of prior SARS-CoV-2 infection and vaccination on Omicron infection

The impact of prior SARS-CoV-2 infection and vaccination on Omicron infection

Rethinking next generation of improved vaccines for mucosa-replicating viruses

Rethinking next generation of improved vaccines for mucosa-replicating viruses

Researchers study congenital abnormalities after COVID-19 infection and vaccination

Researchers study congenital abnormalities after COVID-19 infection and vaccination

Generative AI approach unlocks path to accelerated antibody drug creation for novel therapeutic targets

Generative AI approach unlocks path to accelerated antibody drug creation for novel therapeutic targets

New survey shows increase in COVID-19 vaccine acceptance across 23 countries in 2022

New survey shows increase in COVID-19 vaccine acceptance across 23 countries in 2022

COVID-19 vaccine potency and breadth improved by nanoparticle-conjugated adjuvants

COVID-19 vaccine potency and breadth improved by nanoparticle-conjugated adjuvants

Does the immunization order of vaccine types influence the efficacy of heterologous prime-boost vaccination, especially mRNA and protein-based vaccines?

Does the immunization order of vaccine types influence the efficacy of heterologous prime-boost vaccination, especially mRNA and protein-based vaccines?

Oxford's Ebola vaccine candidate manufactured and shipped to Uganda in just 80 days

Oxford's Ebola vaccine candidate manufactured and shipped to Uganda in just 80 days

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.